Synergistic anti-tumor effects of novel two-domain soluble Fms-like tyrosine kinase-1 and paclitaxel on three-dimensional breast cancer models: implications for targeted therapy
Adel Zaid I Mutahar, Renu Dayal, Bharathi P Salimath · 2025
Read Synergistic anti-tumor effects of novel two-domain soluble Fms-like tyrosine kinase-1 and paclitaxel on three-dimensional breast cancer models: implications for targeted therapy by Adel Zaid I Mutahar, Renu Dayal, Bharathi P Salimath (2025) in the Tower of Babel, a free online library of public-domain works preserved in clean, searchable text. No sign-up. The full text is served as a plain-text file at a predictable URL, where text is present: https://antarctic-labs.com/tower-of-babel/pmc-12751523.txt.
Description
Adel Mutahar, Renu Dayal, and Bharathi Salimath test a drug pair against breast cancer in lab-grown tumor balls in a 2025 study. Ball cultures mimic real tumors better than flat cell layers, including drug resistance. Triple-negative breast cancer is fast-growing and lacks targeted options.
A standard chemo drug alone lost much of its punch in the balls, needing about twenty-five times the flat-culture dose. Adding a new two-domain protein that soaks up a vessel growth signal cut the needed dose roughly tenfold in one cell line. A rival antibody gave only modest help. The pair also shrank balls, slowed spread traits, and cut vessel growth signals. In mixed balls with vessel cells, a key adhesion pathway faded as well.
Catalog record
| CREATOR | Adel Zaid I Mutahar, Renu Dayal, Bharathi P Salimath |
|---|---|
| YEAR | 2025 |
| COLLECTION | PAPERS |
| FORMAT | TXT |
| FILE SIZE | 57 KB |
| VERSION | 1.0 |
| LICENSE | CC BY 4.0 |
| RIGHTS | CC BY |
| SOURCE | Europe PMC |